Publications by authors named "Sebastian Frechen"

Claim this Profile
D
Development of a novel physiologically based biopharmaceutics modeling (PBBM) framework using the open systems pharmacology suite, part 1: in vitro modeling of vericiguat.
Paul Vrenken, Maria Vertzoni, Sebastian Frechen, Juri Solodenko, Michaela Meyer

Eur J Pharm Sci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a novel physiologically based biopharmaceutics modeling (PBBM) framework using the open systems pharmacology suite, part 2: in vivo pharmacokinetic modeling of vericiguat.
Paul Vrenken, Maria Vertzoni, Sebastian Frechen, Juri Solodenko, Michaela Meyer

Eur J Pharm Sci· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development.
Simeon Rüdesheim, Helena Leonie Hanae Loer, Denise Feick, Fatima Zahra Marok, Laura Maria Fuhr, Sebastian Frechen

Clin Pharmacol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first-pass metabolism?
Justine Henriot, André Dallmann, François Dupuis, Jérémy Perrier, Sebastian Frechen

CPT Pharmacometrics Syst Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data.
Stefan Willmann, Adam Lloyd, Rupert Austin, Shiju Joseph, Alexander Solms, Sebastian Frechen

CPT Pharmacometrics Syst Pharmacol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-Depth Analysis of the Selection of PBPK Modeling Tools: Bibliometric and Social Network Analysis of the Open Systems Pharmacology Community.
André Dallmann, Donato Teutonico, Stephan Schaller, Rolf Burghaus, Sebastian Frechen

J Clin Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling.
Friederike Kanefendt, André Dallmann, Huijun Chen, Klaus Francke, Tianxing Liu, Sebastian Frechen

Clin Pharmacol Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for Vericiguat.
Sebastian Frechen, Ibrahim Ince, André Dallmann, Michael Gerisch, Natalia A Jungmann

CPT Pharmacometrics Syst Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging the use of in vitro and computational methods to support the development of enabling oral drug products: An InPharma commentary.
Christos Reppas, Martin Kuentz, Annette Bauer-Brandl, Sara Carlert, André Dallmann, Sebastian Frechen

Eur J Pharm Sci· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug-drug-gene interaction network.
Denise Feick, Simeon Rüdesheim, Fatima Zahra Marok, Dominik Selzer, Helena Leonie Hanae Loer, Sebastian Frechen

CPT Pharmacometrics Syst Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions.
Helena Leonie Hanae Loer, Denise Feick, Simeon Rüdesheim, Dominik Selzer, Matthias Schwab, Sebastian Frechen

CPT Pharmacometrics Syst Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
Sebastian Frechen, Amin Rostami-Hodjegan

Pharm Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone.
Thomas Wendl, Sebastian Frechen, Michael Gerisch, Roland Heinig, Thomas Eissing

CPT Pharmacometrics Syst Pharmacol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.
Sebastian Frechen, Juri Solodenko, Thomas Wendl, André Dallmann, Ibrahim Ince

CPT Pharmacometrics Syst Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children.
Ibrahim Ince, André Dallmann, Sebastian Frechen, Katrin Coboeken, Christoph Niederalt

J Clin Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
Xia Li, Lisa Junge, Max Taubert, Anabelle von Georg, Dominik Dahlinger, Sebastian Frechen

J Clin Pharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Lucia Nogova, Christian Mattonet, Matthias Scheffler, Max Taubert, Masyar Gardizi, Sebastian Frechen

Cancer Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Xia Li, Sebastian Frechen, Daniel Moj, Thorsten Lehr, Max Taubert

Clin Pharmacokinet· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Denise Türk, Nina Hanke, Sarah Wolf, Sebastian Frechen, Thomas Eissing

Clin Pharmacokinet· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences.
Jörg Lippert, Rolf Burghaus, Andrea Edginton, Sebastian Frechen, Mats Karlsson

CPT Pharmacometrics Syst Pharmacol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
Ibrahim Ince, Juri Solodenko, Sebastian Frechen, André Dallmann, Christoph Niederalt

J Clin Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
Hannah Britz, Nina Hanke, Anke-Katrin Volz, Olav Spigset, Matthias Schwab, Sebastian Frechen

CPT Pharmacometrics Syst Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.
Niladri Chattopadhyay, Tobias Kanacher, Manuela Casjens, Sebastian Frechen, Sandra Ligges

Br J Clin Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
Nina Hanke, Sebastian Frechen, Daniel Moj, Hannah Britz, Thomas Eissing

CPT Pharmacometrics Syst Pharmacol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome.
Dominik Dahlinger, Sevinc Aslan, Markus Pietsch, Sebastian Frechen, Uwe Fuhr

Ther Adv Urol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis